Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19629265 | 0.83 | TSHR (0.42) | CES2CES1F2RL1PDE2A | |
| SCHEMBL18891691 | 0.82 | CES2 (0.39) | CES2CES1ALDH1A1HPGD | |
| SCHEMBL24222540 | 0.78 | CFD (0.38) | CES2CES1F2RL1 | |
| SCHEMBL28793509 | 0.78 | CES2 (0.41) | CES2CES1 | |
| SCHEMBL12891864 | 0.78 | CES2 (0.42) | CES2CES1F2RL1PDE2A | |
| SCHEMBL23101943 | 0.78 | GAA (0.33) | ALDH1A1HPGDEPHX2GAA | |
| SCHEMBL22304548 | 0.77 | GCGR (0.33) | — | |
| Hydrochloric Acid SCHEMBL3747297 | 0.76 | TAAR1 (0.38) | CES2CES1PDE2A | |
| SCHEMBL19987464 | 0.76 | LMNA (0.39) | PDE2A | |
| SCHEMBL19098547 | 0.74 | MC4R (0.39) | CES2CES1F2RL1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3896521-B1 | POLYMER, PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING METHOD, METHOD OF FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC COMPONENT | SHINETSU CHEMICAL CO (JP) | 2022-12-14 | — | — | EP | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | CES2 2446/4885CES1 3523/4885F2RL1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.